06:09:41 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandStorbritannien
ListaLarge Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AstraZeneca är ett globalt bioläkemedelsbolag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom terapiområdena som berör andningsvägar, hjärta/kärl/metabolism och cancer. Utöver huvudverksamheten är bolaget även aktiva inom autoimmunitet, neurovetenskap och infektion. AstraZeneca är verksamma inom samtliga globala regioner och har sitt huvudkontor i Cambridge, Storbritannien.

Kalender

2021-07-29 Kvartalsrapport 2021-Q2
2021-04-30 Kvartalsrapport 2021-Q1
2021-02-25 Halvårsutdelning AZN 15.76
2021-02-11 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-13 Halvårsutdelning AZN 7.87
2020-07-30 Kvartalsrapport 2020-Q2
2020-04-29 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-27 Halvårsutdelning AZN 18.32
2020-02-14 Bokslutskommuniké 2019
2019-08-08 Halvårsutdelning AZN 8.49
2019-04-26 Årsstämma 2019
2019-02-28 Halvårsutdelning AZN 17.46
2019-02-14 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-09 Halvårsutdelning AZN 7.92
2018-07-26 Kvartalsrapport 2018-Q2
2018-05-18 Kvartalsrapport 2018-Q1
2018-05-18 Årsstämma 2018
2018-02-15 Halvårsutdelning AZN 14.97
2018-02-02 Bokslutskommuniké 2017
2017-11-09 Kvartalsrapport 2017-Q3
2017-08-10 Halvårsutdelning AZN 7.4
2017-07-27 Kvartalsrapport 2017-Q2
2017-04-27 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-16 Halvårsutdelning AZN 16.57
2017-02-02 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-11 Halvårsutdelning AZN 7.81
2016-07-28 Kvartalsrapport 2016-Q2
2016-04-29 Årsstämma 2016
2016-04-29 Kvartalsrapport 2016-Q1
2016-02-18 Halvårsutdelning AZN 16.26
2016-02-04 Bokslutskommuniké 2015
2015-11-05 Kvartalsrapport 2015-Q3
2015-08-13 Halvårsutdelning AZN 7.71
2015-07-30 Kvartalsrapport 2015-Q2
2015-04-24 Kvartalsrapport 2015-Q1
2015-04-24 Årsstämma 2015
2015-02-19 Halvårsutdelning AZN 15.62
2015-02-05 Bokslutskommuniké 2014
2014-11-06 Kvartalsrapport 2014-Q3
2014-08-13 Halvårsutdelning AZN 6.2
2014-07-31 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-04-24 Årsstämma 2014
2014-02-19 Halvårsutdelning AZN 12.41
2014-02-06 Bokslutskommuniké 2013
2013-10-31 Kvartalsrapport 2013-Q3
2013-08-14 Halvårsutdelning AZN 5.92
2013-08-01 Analytiker möte 2013
2013-08-01 Kvartalsrapport 2013-Q2
2013-04-25 Kvartalsrapport 2013-Q1
2013-04-25 Årsstämma 2013
2013-02-13 Halvårsutdelning AZN 12.08
2013-01-31 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-10-25 Analytiker möte 2012
2012-08-08 Halvårsutdelning AZN 6.26
2012-07-26 Kvartalsrapport 2012-Q2
2012-04-26 Kvartalsrapport 2012-Q1
2012-04-26 Årsstämma 2012
2012-02-15 Halvårsutdelning AZN 13.21
2012-02-02 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-03 Halvårsutdelning AZN 5.33
2011-07-28 Kvartalsrapport 2011-Q2
2011-04-28 Kvartalsrapport 2011-Q1
2011-04-28 Årsstämma 2011
2011-02-02 Halvårsutdelning AZN 11.99
2011-01-27 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-04 Halvårsutdelning AZN 5.12
2010-07-29 Kvartalsrapport 2010-Q2
2010-04-29 Kvartalsrapport 2010-Q1
2010-02-03 Halvårsutdelning AZN 12.43
2010-01-28 Bokslutskommuniké 2009
2009-10-29 Kvartalsrapport 2009-Q3
2009-08-05 Halvårsutdelning AZN 4.41
2009-07-30 Kvartalsrapport 2009-Q2
2009-04-30 Årsstämma 1
2009-04-30 Kvartalsrapport 2009-Q1
2009-02-04 Halvårsutdelning AZN 12.02
2008-08-06 Halvårsutdelning AZN 3.34
2008-02-06 Halvårsutdelning AZN 8.61
2007-08-08 Halvårsutdelning AZN 3.49
2007-02-07 Halvårsutdelning AZN 8.6
2006-08-09 Halvårsutdelning AZN 3.6
2006-02-08 Halvårsutdelning AZN 7.02
2005-08-10 Halvårsutdelning AZN 2.99
2005-02-09 Halvårsutdelning AZN 4.497
2004-08-11 Halvårsutdelning AZN 2.2
2004-02-18 Halvårsutdelning AZN 3.91
2003-08-20 Halvårsutdelning AZN 2.07
2003-02-19 Halvårsutdelning AZN 3.99
2002-08-21 Halvårsutdelning AZN 2.21
2002-02-20 Halvårsutdelning AZN 5.01
2001-08-22 Halvårsutdelning AZN 2.44
2001-02-21 Halvårsutdelning AZN 4.49
2000-09-04 Halvårsutdelning AZN 2.1
2000-03-08 Halvårsutdelning AZN 4.01
1999-09-06 Halvårsutdelning AZN 1.89
1999-04-01 Split AZN 1:0.5045
1997-05-26 Split AZN 1:2
1993-06-14 Split AZN 1:5
1987-06-04 Split AZN 1:2
2021-01-29 09:46:40

Data at WCLC showed patients in the practice-changing ADAURA Phase III trial maintained their quality of life based on patient-reported outcomes

New data reinforce the ability of Tagrisso to penetrate the blood-brain barrier in patients with central nervous system metastases

Results from an exploratory analysis of the positive ADAURA Phase III trial showed AstraZeneca's Tagrisso (osimertinib) extended disease-free survival (DFS) in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) regardless of prior adjuvant chemotherapy treatment or stage of disease, building on the unprecedented primary DFS results for Tagrisso in the adjuvant setting announced last year (https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-demonstrated-unprecedented-disease-free-survival-in-the-adjuvant-treatment-of-stage-ib-iiia-patients-with-egfr-mutated-lung-cancer.html). Results from ADAURA were presented during the 2020 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC) and featured in the Press Programme.

In this exploratory analysis of the overall trial population, adjuvant Tagrisso reduced the risk of disease recurrence or death by 84% in patients who had been treated with prior adjuvant chemotherapy (based on a hazard ratio [HR] of 0.16, 95% confidence interval [CI] 0.10-0.26) and by 77% in patients who had not (HR 0.23; 95% CI 0.13-0.40). DFS benefits were similar across each stage of disease.

In addition, a separate exploratory post-hoc analysis of patient-reported outcomes in ADAURA showed that patients treated with Tagrisso maintained their quality of life, with no clinically meaningful differences in physical or mental health measures in the Tagrisso and placebo arms.

Yi-Long Wu, MD, FACS, Tenured Professor of the Lung Cancer Institute at Guangdong Provincial People's Hospital and Academy of Medical Sciences in Guangzhou, China, and a principal investigator in the ADAURA Phase III trial, said: "The overwhelming disease-free survival benefit in patients in ADAURA already supported the role of Tagrisso as a pioneering therapy in the adjuvant treatment of EGFR-mutated non-small cell lung cancer. This latest analysis shows the magnitude of that benefit is consistent with or without prior adjuvant chemotherapy, and regardless of disease stage, reinforcing the critical role of Tagrisso in this setting."  

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: "These new data show that Tagrisso provides transformative benefits independent of prior chemotherapy treatment, preventing lung cancer from returning while allowing patients to sustain their quality of life. Following the recent approval of Tagrisso in the US in the adjuvant setting, we continue to work urgently with regulatory authorities globally to bring this new standard of care to patients with early-stage lung cancer."

Exploratory DFS analysis with and without chemotherapy (CTx)

OSI: Tagrisso; PBO: placebo

Stage IB Stage II Stage IIIA Stage IB
-IIIA
OSI PBO OSI PBO OSI PBO OSI PBO
With CTx n=28 n=30 n=81 n=85 n=94 n=92 n=203 n=207
DFS 4 (14) 11 6 (7) 36 12 (13) 56 22 (11) 103
eventspatients (37) (42) (61) (50)
(%)
DFS HR(95% CI) NC(NC, NC) 0.15(0.06, 0.13(0.06, 0.16(0.10,
0.32) 0.23) 0.26)

Without CTx n=78 n=76 n=37 n=33 n=21 n=27 n=136 n=136
DFS 7 (9) 18 5 (14) 16 3 (14) 22 15 (11) 56
eventspatients (24) (48) (81) (41)
(%)
DFS HR(95% CI) 0.38(0.15, 0.20(0.07, 0.10(0.02, 0.23(0.13,
0.88) 0.52) 0.29) 0.40)

In the ADAURA Phase III trial, chemotherapy use was balanced across the two treatment arms, with 60% of patients receiving prior adjuvant chemotherapy. In line with uptake observed in prior studies and clinical practice, younger patients (<70 years) and those with more advanced disease were more likely to have prior adjuvant chemotherapy.[1,2] Treatment with chemotherapy did not vary according to a patient's performance status.

The safety and tolerability of Tagrisso was consistent with previous trials in the metastatic EGFRm NSCLC setting. Adverse events at Grade 3 or higher from all causes occurred in 20% of patients in the Tagrisso arm versus 13% in the placebo arm as assessed by investigators.

Primary results of ADAURA, which were published in The New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa2027071) in September 2020, showed adjuvant treatment with Tagrisso reduced the risk of disease recurrence or death by 83% (HR 0.17; 95% CI 0.12-0.23; p<0.0001) among patients with Stage II and IIIA EGFRm NSCLC and, as shown in a prespecified exploratory analysis, demonstrated a clinically meaningful improvement in central nervous system (CNS) DFS compared to placebo.

Additional Tagrisso highlights at WCLC

In addition to these ADAURA analyses, several other presentations and posters for Tagrisso across lung cancer settings and in novel combinations were featured during WCLC, including:
  • Results from the ODIN BM Phase I trial, which support the efficacy and uniform brain penetration of Tagrisso in patients with CNS metastases as reported in previous clinical trials. This trial used a micro dose of intravenous Tagrisso detectable on PET scans, which showed rapid, high and widespread brain exposure of Tagrisso in both the healthy tissue and CNS metastases of four patients with EGFRm NSCLC. Results also showed that Tagrisso markedly reduced CNS metastases in patients following three to four weeks of daily oral treatment
  • Final results from two expansion cohorts of the TATTON Phase Ib trial, which support the potential of Tagrisso plus savolitinib, a selective inhibitor of mesenchymal epithelial transition (c-MET) factor receptor tyrosine kinase, to overcome MET-based resistance in patients with NSCLC whose disease has progressed on prior EGFR-tyrosine kinase inhibitor (TKI) treatment. The safety profile of Tagrisso plus savolitinib was consistent with previous reports. The combination is currently being tested in the ongoing SAVANNAH and ORCHARD Phase II trials
  • The design of a Phase I study exploring Tagrisso in combination with patritumab deruxtecan (U3-1402) in patients with locally advanced or metastatic EGFRm NSCLC who progressed during or after prior treatment with Tagrisso alone[3]
  • The design of the NeoADAURA Phase III trial testing the benefit of treating patients with resectable Stage II-IIIB NSCLC with neoadjuvant Tagrisso as monotherapy or in combination with a choice of standard platinum-based chemotherapies versus chemotherapy with placebo. Patient recruitment for this trial is ongoing

Tagrisso was recently approved in the US for the adjuvant treatment of adult patients with early-stage EGFRm NSCLC after tumour resection with curative intent based on the ADAURA Phase III trial. This indication is under priority review in China and regulatory review in the EU; additional global submission discussions are ongoing. Tagrisso is also approved for the 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC and for the treatment of locally advanced or metastatic EGFR T790M mutation-positive NSCLC in the US, Japan, China, the EU and many other countries around the world.

Lung cancer

Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-fifth of all cancer deaths.[4] Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% classified as NSCLC.[5] The majority of all NSCLC patients are diagnosed with advanced disease while approximately 25-30% present with resectable disease at diagnosis.[6-8] Early-stage lung cancer diagnoses are often only made when the cancer is found on imaging for an unrelated condition.[9,10]

For patients with resectable tumours, the majority of patients eventually develop recurrence despite complete tumour resection and adjuvant chemotherapy.[11]

Approximately 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia have EGFRm NSCLC.[12-14] These patients are particularly sensitive to treatment with an EGFR-TKI which blocks the cell-signalling pathways that drive the growth of tumour cells.[15]

ADAURA

ADAURA is a randomised, double-blind, global, placebo-controlled Phase III trial in the adjuvant treatment of 682 patients with Stage IB, II and IIIA EGFRm NSCLC following complete tumour resection and adjuvant chemotherapy as indicated. Patients were treated with Tagrisso 80mg once-daily oral tablets or placebo for three years or until disease recurrence.

The trial enrolled patients in more than 200 centres across more than 20 countries, including the US, in Europe, South America, Asia and the Middle East. The primary endpoint was DFS in Stage II and IIIA patients and a key secondary endpoint was DFS in Stage IB, II and IIIA patients.

The data readout was originally anticipated in 2022. In April 2020, an Independent Data Monitoring Committee recommended for the trial to be unblinded two years early based on a determination of overwhelming efficacy. Investigators and patients continue to participate and remain blinded to treatment. The trial will continue to assess overall survival.

Tagrisso

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with clinical activity against CNS metastases.

Tagrisso (40mg and 80mg once-daily oral tablets) is approved in many countries around the world, including the US, Japan, China and in the EU, for the 1st-line treatment of EGFRm advanced NSCLC and EGFR T790M mutation-positive advanced NSCLC. Tagrisso is also approved in the US and several other countries for the adjuvant treatment of adults with early-stage EGFRm NSCLC after tumour resection, with further global submissions ongoing.

Tagrisso has been used to treat approximately 215,000 patients across indications worldwide.

AstraZeneca in lung cancer

AstraZeneca has a comprehensive portfolio of approved and potential new medicines in late-stage development for the treatment of different forms of lung cancer spanning different histologies, several stages of disease, lines of therapy and modes of action.

AstraZeneca aims to address the unmet needs of patients with EGFRm tumours as a genetic driver of disease with the approved medicines Iressa (gefitinib) and Tagrisso and its ongoing LAURA, NeoADAURA and FLAURA2 Phase III trials. AstraZeneca is committed to addressing tumour mechanisms of resistance through the ongoing SAVANNAH and ORCHARD Phase II trials, which test Tagrisso in combination with savolitinib, a selective inhibitor of c-MET receptor tyrosine kinase, along with other potential new medicines.

AstraZeneca in oncology

AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients' lives and the Company's future. With seven new medicines launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers.

By harnessing the power of six scientific platforms - Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response, Antibody Drug Conjugates, Epigenetics, and Cell Therapies - and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment, and one day, eliminate cancer as a cause of death.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).

Contacts

For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).

References

1. Chouaid, C, et al. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer 2018;124:310-316. 
2. Buck, P.O., et al. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices. Clin Lung Cancer 2015;16:486-495.
3. Trial collaboration with Daiichi Sankyo which maintains exclusive rights to patritumab deruxtecan.
4. World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Available at https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed January 2021.
5. LUNGevity Foundation. Types of Lung Cancer. Available at  https://lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer. Accessed January 2021.
6. Cagle P, et al. Lung Cancer Biomarkers: Present Status and Future Developments. Archives Pathology Lab Med. 2013;137:1191-1198.
7. Le Chevalier T, et al. Adjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer: Where is it Going? Ann Oncol. 2010;21:196-8.
8. Datta D, et al. Preoperative Evaluation of Patients Undergoing Lung Resection Surgery. Chest. 2003;123: 2096-2103.
9. Sethi S, et al. Incidental Nodule Management - Should There Be a Formal Process?. Journal of Thorac Onc. 2016:8;S494-S497.
10. LUNGevity Foundation. Screening and Early Detection. Available at https://lungevity.org/for-patients-caregivers/lung-cancer-101/screening-early-detection. Accessed January 2021.
11. Pignon, J.P., et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559.
12. Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013:6;2800-12.
13. Keedy V.L., et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011:29;2121-27.
14. Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. J Clin Pathol. 2013:66;79-89.
15. Cross DA, et al. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discov. 2014;4(9):1046-1061.